Natter, Inc. a global leader in cell-free DNA (cfDNA) testing ,today, the company announced the pricing of its underwritten public offering of 11,430,000 shares of common stock at a public price of $35.00 per share.
The offering is scheduled to close on November 18, 2022, subject to usual closing conditions. Natera has also granted the underwriters a 30-day option to acquire up to an additional 1,714,500 shares of common stock at the public offering price less underwriting discounts and fees.
The offering’s joint book-running managers are Morgan Stanley, Cowen, and SVB Securities. Baird is serving as the offering’s co-manager.
The securities described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission on November 15, 2022. The offering will be made only by means of an effective registration statement, including a preliminary prospectus and, when available, final prospectus, copies of which may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; or SVB Securities LLC Attention: Syndicate Department 53 State Street, 40th Floor Boston, MA 02109 by telephone at 1-800-808-7525 ex. 6132 or by email at syndicate@svbsecurities.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction
SOURCE – Natera, Inc.
